Trial Outcomes & Findings for Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections (NCT NCT02045797)

NCT ID: NCT02045797

Last Updated: 2017-11-17

Results Overview

Cure rate and withdrawal rate data points was jointly assessed in a composite endpoint for all participants who received at least one dose of GSK2140944. Cure rate was defined as the percentage of participants exhibiting clinical improvement (=\>20% reduction in overall lesion area) at the early efficacy visit. Withdrawal rate was defined as the percentage of participants who withdrew from study treatment due to a drug-related adverse event (AE) at any point while on treatment.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

126 participants

Primary outcome timeframe

Up to Day 3

Results posted on

2017-11-17

Participant Flow

This study was conducted at 13 centers in the United States from 24 March 2014 to 22 July 2015.

A total of 126 participants were randomly assigned to study treatment (all randomized population). A total of 122 participants, who received study treatment, were included in the Modified Intent-to-Treat population (mITT) and safety populations. The mITT population is used in overall study numbers and demographic information.

Participant milestones

Participant milestones
Measure	Gepotidacin 750 mg q12h Participants received GSK2140944 750 milligrams (mg) intravenous (IV) every 12 hours (q12h; twice daily \[BID\]) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h Participants received GSK21409447 1000 mg IV every 8 hours (q8h) three times a day (TID) on Day 1 and Day 2 . Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Overall Study STARTED	58	39	25
Overall Study COMPLETED	51	32	24
Overall Study NOT COMPLETED	7	7	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Gepotidacin 750 mg q12h Participants received GSK2140944 750 milligrams (mg) intravenous (IV) every 12 hours (q12h; twice daily \[BID\]) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h Participants received GSK21409447 1000 mg IV every 8 hours (q8h) three times a day (TID) on Day 1 and Day 2 . Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Overall Study Adverse Event	3	1	0
Overall Study Lack of Efficacy	1	0	0
Overall Study Lost to Follow-up	2	3	1
Overall Study Physician Decision	0	1	0
Overall Study Withdrawal by Subject	1	2	0

Baseline Characteristics

Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.	Total n=122 Participants Total of all reporting groups
Age, Continuous	44.3 Years STANDARD_DEVIATION 11.35 • n=5 Participants	44.6 Years STANDARD_DEVIATION 10.76 • n=7 Participants	45.8 Years STANDARD_DEVIATION 12.64 • n=5 Participants	44.7 Years STANDARD_DEVIATION 11.36 • n=4 Participants
Sex: Female, Male Female	18 Participants n=5 Participants	12 Participants n=7 Participants	5 Participants n=5 Participants	35 Participants n=4 Participants
Sex: Female, Male Male	40 Participants n=5 Participants	27 Participants n=7 Participants	20 Participants n=5 Participants	87 Participants n=4 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	2 Participants n=4 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants
Race (NIH/OMB) Black or African American	1 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	3 Participants n=4 Participants
Race (NIH/OMB) White	55 Participants n=5 Participants	36 Participants n=7 Participants	24 Participants n=5 Participants	115 Participants n=4 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants

PRIMARY outcome

Timeframe: Up to Day 3

Population: Modified Intent-to-Treat (MITT) population consisted of all randomized participants who received at least one dose of study medication.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate Number Cured	48 Participants	28 Participants	23 Participants
Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate Number Withdrawn	1 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to Day 3

Population: MITT population.

The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as a reduction in the total surface area of the lesion (as calculated by digital imaging) of \>=20% compared to Baseline and no administration of additional antibacterial therapy for the lesion under study. Clinical failure was defined as death of participant; increase or insufficient decrease (i.e., \<20%) in the area (as calculated by digital imaging) of the lesion or administration of non-trial antibacterial drug therapy for treatment of the lesion under study before the primary efficacy endpoint assessment. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Participants With Clinical Response and Outcome at Early Efficacy Visit Clinical Success	48 Participants	28 Participants	23 Participants
Number of Participants With Clinical Response and Outcome at Early Efficacy Visit Clinical Failure	7 Participants	7 Participants	2 Participants
Number of Participants With Clinical Response and Outcome at Early Efficacy Visit Unable to Determine	3 Participants	4 Participants	0 Participants

SECONDARY outcome

Timeframe: Day 12 to Day 18

Population: MITT population.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Participants With Clinical Response and Outcome at the Post Therapy Visit (Day 12-18) Clinical Success	52 Participants	32 Participants	21 Participants
Number of Participants With Clinical Response and Outcome at the Post Therapy Visit (Day 12-18) Clinical Failure	1 Participants	1 Participants	1 Participants
Number of Participants With Clinical Response and Outcome at the Post Therapy Visit (Day 12-18) Unable to Determine	5 Participants	6 Participants	3 Participants

SECONDARY outcome

Timeframe: Day 21 to Day 28

Population: MITT population.

The assessment was used to determine whether to continue the participant in the study. Clinical response was assessed as either a clinical success or a clinical failure and the clinical outcome was subsequently determined programmatically, based on the clinical response. Clinical success was defined as no increase in the total surface area of the lesion (as calculated by digital imaging) compared to post therapy visit and no further administration of antibacterial therapy for the lesion under study. Clinical recurrence was defined as death of participant; increase in the area of the lesion compared to post therapy visit or administration of additional antibacterial therapy for the lesion under study before the efficacy endpoint assessment for participants who were a clinical success at post therapy visit. In addition when the participant refused to consent to clinical examination, the clinical outcome was assessed as unable to determine with subsequent response as failure.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Participants With Clinical Response and Outcome at the Final Follow up Visit (Day 21-28) Clinical Success	50 Participants	28 Participants	20 Participants
Number of Participants With Clinical Response and Outcome at the Final Follow up Visit (Day 21-28) Clinical Failure	1 Participants	1 Participants	1 Participants
Number of Participants With Clinical Response and Outcome at the Final Follow up Visit (Day 21-28) Clinical Recurrence	2 Participants	1 Participants	1 Participants
Number of Participants With Clinical Response and Outcome at the Final Follow up Visit (Day 21-28) Unable to Determine	5 Participants	9 Participants	3 Participants

SECONDARY outcome

Timeframe: Up to Day 3

Population: Modified Microbiological ITT consisted of all randomized participants who received at least one dose of study medication and had a Gram-positive pathogens identified from their Baseline bacteriology lesion sample.

The microbiological outcome was determined by comparing Baseline bacteriology lesion sample, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for SA in lesion sample has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=37 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=28 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=11 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Staphylococcus Aureus (SA) Pathogen in Lesion Sample Microbiological Success, Presumed Eradication	24 Number of pathogens	17 Number of pathogens	9 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Staphylococcus Aureus (SA) Pathogen in Lesion Sample Microbiological Success, Eradication	0 Number of pathogens	2 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Staphylococcus Aureus (SA) Pathogen in Lesion Sample Microbiological Failure, Persistence	11 Number of pathogens	3 Number of pathogens	2 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Staphylococcus Aureus (SA) Pathogen in Lesion Sample Microbiological Failure, Presumed Persistence	4 Number of pathogens	6 Number of pathogens	0 Number of pathogens

SECONDARY outcome

Timeframe: Day 3

Population: Modified Microbiological ITT population.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=28 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=20 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=5 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-resistant Staphylococcus Aureus (MRSA) in Lesion Sample Microbiological Success, Eradication	0 Number of pathogens	2 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-resistant Staphylococcus Aureus (MRSA) in Lesion Sample Microbiological Success, Presumed Eradication	18 Number of pathogens	10 Number of pathogens	4 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-resistant Staphylococcus Aureus (MRSA) in Lesion Sample Microbiological Failure, Persistence	7 Number of pathogens	3 Number of pathogens	1 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-resistant Staphylococcus Aureus (MRSA) in Lesion Sample Microbiological Failure, Presumed Persistence	4 Number of pathogens	5 Number of pathogens	0 Number of pathogens

SECONDARY outcome

Timeframe: Up to Day 3

Population: Modified Microbiological ITT population.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=10 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=8 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=6 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-susceptible Staphylococcus Aureus (MSSA) in Lesion Sample Microbiological Success, Presumed Eradication	6 Number of pathogens	7 Number of pathogens	5 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-susceptible Staphylococcus Aureus (MSSA) in Lesion Sample Microbiological Failure, Persistence	4 Number of pathogens	0 Number of pathogens	1 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Methicillin-susceptible Staphylococcus Aureus (MSSA) in Lesion Sample Microbiological Failure, Presumed Persistence	0 Number of pathogens	1 Number of pathogens	0 Number of pathogens

SECONDARY outcome

Timeframe: Up to Day 3

Population: Modified Microbiological ITT population.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=4 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=4 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=3 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Success, Eradication	2 Number of pathogens	2 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Success, Presumed Eradication	0 Number of pathogens	1 Number of pathogens	3 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Presumed Persistence	1 Number of pathogens	1 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Unable to Determine	1 Number of pathogens	0 Number of pathogens	0 Number of pathogens

SECONDARY outcome

Timeframe: Up to Day 3

Population: Modified Microbiological ITT population.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=40 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=29 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=13 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Success, Eradication	2 Number of pathogens	4 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Success, Presumed Eradication	24 Number of pathogens	18 Number of pathogens	12 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Persistence	11 Number of pathogens	3 Number of pathogens	2 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Presumed Persistence	5 Number of pathogens	7 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Unable to Determine	1 Number of pathogens	0 Number of pathogens	0 Number of pathogens

SECONDARY outcome

Timeframe: Up to Day 3

Population: Modified Microbiological ITT population.

The microbiological outcome was determined by comparing Baseline bacteriology blood culture, to the culture results at early efficacy visit. The corresponding microbiological response (success or failure) by participant was then assigned. Microbiological eradication or persistence was defined as culture documented elimination or presence of Baseline pathogens from a bacteriology specimen taken at early efficacy visit respectively. Participant was considered to have outcome of presumed microbiological eradication or persistence when the participant was a clinical success or clinical failure and no bacteriological specimen was obtained at early efficacy visit respectively. When the determination of Baseline pathogen microbiological response could not be made, the outcome was considered as unable to determine. The data for SA, MRSA and all Gram-positive aerobic pathogens in blood sample has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=2 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample SA, Microbiological Success, Eradication	2 Number of pathogens	—	—
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample MRSA, Microbiological Success, Eradication	2 Number of pathogens	—	—
Number of Pathogens With Microbiological Response and Outcome at Early Efficacy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample Aerobic, Microbiological Success, Eradication	2 Number of pathogens	—	—

SECONDARY outcome

Timeframe: Day 12 to Day 18

Population: Modified Microbiological ITT population.

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained at post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA in lesion sample has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=37 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=28 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=11 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA Pathogen in Lesion Sample Microbiological Success, Presumed Eradication	32 Number of pathogens	24 Number of pathogens	8 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA Pathogen in Lesion Sample Microbiological Success, Eradication	3 Number of pathogens	1 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA Pathogen in Lesion Sample Microbiological Failure, Presumed Persistence	3 Number of pathogens	2 Number of pathogens	1 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA Pathogen in Lesion Sample Microbiological Failure, Presumed Recurrence	1 Number of pathogens	1 Number of pathogens	2 Number of pathogens

SECONDARY outcome

Timeframe: Day 12 to Day 18

Population: Modified Microbiological ITT population.

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MRSA in lesion sample has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=28 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=20 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=5 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MRSA in Lesion Sample Microbiological Success, Eradication	3 Number of pathogens	0 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MRSA in Lesion Sample Microbiological Success, Presumed Eradication	22 Number of pathogens	17 Number of pathogens	4 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MRSA in Lesion Sample Microbiological Failure, Presumed Persistence	3 Number of pathogens	2 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MRSA in Lesion Sample Microbiological Failure, Presumed Recurrence	1 Number of pathogens	1 Number of pathogens	1 Number of pathogens

SECONDARY outcome

Timeframe: Day 12 to Day 18

Population: Modified Microbiological ITT population.

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for MSSA in lesion sample has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=10 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=8 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=6 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MSSA in Lesion Sample Microbiological Success, Eradication	0 Number of pathogens	1 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MSSA in Lesion Sample Microbiological Success, Presumed Eradication	10 Number of pathogens	7 Number of pathogens	4 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MSSA in Lesion Sample Microbiological Failure, Presumed Persistence	0 Number of pathogens	0 Number of pathogens	1 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for MSSA in Lesion Sample Microbiological Failure, Presumed Recurrence	0 Number of pathogens	0 Number of pathogens	1 Number of pathogens

SECONDARY outcome

Timeframe: Day 12 to Day 18

Population: Modified Microbiological ITT population.

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=4 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=4 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=3 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Success, Presumed Eradication	3 Number of pathogens	3 Number of pathogens	2 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Presumed Persistence	0 Number of pathogens	1 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Presumed Recurrence	1 Number of pathogens	0 Number of pathogens	1 Number of pathogens

SECONDARY outcome

Timeframe: Day 12 to Day 18

Population: Modified Microbiological ITT population.

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=40 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=29 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=13 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Success, Eradication	3 Number of pathogens	1 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Success, Presumed Eradication	35 Number of pathogens	27 Number of pathogens	10 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Presumed Persistence	3 Number of pathogens	3 Number of pathogens	1 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Presumed Recurrence	2 Number of pathogens	1 Number of pathogens	3 Number of pathogens

SECONDARY outcome

Timeframe: Day 12 to Day 18

Population: Modified Microbiological ITT population.

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at post therapy visit. Corresponding response (success or failure) was then assigned. Microbiological eradication or persistence was culture documented elimination or presence of Baseline pathogens from a specimen taken at post therapy visit respectively. Presence of pathogens which was presumed to be eradicated at early efficacy visit was microbiological recurrence. Presumed microbiological eradication or persistence was when there was a clinical success or failure and no bacteriological specimen was obtained post therapy respectively. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at post therapy visit for pathogens presumed eradicated at early efficacy visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=2 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample SA, Microbiological Success, Presumed Eradication	2 Number of pathogens	—	—
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample MRSA, Microbiological Success,Presumed Eradication	2 Number of pathogens	—	—
Number of Pathogens With Microbiological Response and Outcome at Post Therapy Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample Aerobic,MicrobiologicalSuccess,PresumedEradication	2 Number of pathogens	—	—

SECONDARY outcome

Timeframe: Day 21 to Day 28

Population: Modified Microbiological ITT.

Microbiological outcome was determined by comparing Baseline lesion sample, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA pathogen in lesion sample has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=37 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=28 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=11 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA Pathogen in Lesion Sample Microbiological Success, Eradication	1 Number of pathogens	0 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA Pathogen in Lesion Sample Microbiological Success, Presumed Eradication	33 Number of pathogens	21 Number of pathogens	8 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA Pathogen in Lesion Sample Microbiological Failure, Presumed Recurrence	1 Number of pathogens	4 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA Pathogen in Lesion Sample Microbiological Failure, Unable to Determine	4 Number of pathogens	3 Number of pathogens	3 Number of pathogens

SECONDARY outcome

Timeframe: Day 21 to Day 28

Population: Modified Microbiological ITT population.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=28 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=20 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=5 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MRSA in Lesion Sample Microbiological Success, Eradication	1 Number of pathogens	0 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MRSA in Lesion Sample Microbiological Success, Presumed Eradication	23 Number of pathogens	14 Number of pathogens	4 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MRSA in Lesion Sample Microbiological Failure, Presumed Recurrence	1 Number of pathogens	3 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MRSA in Lesion Sample Microbiological Failure, Unable to Determine	4 Number of pathogens	3 Number of pathogens	1 Number of pathogens

SECONDARY outcome

Timeframe: Day 21 to Day 28

Population: Modified Microbiological ITT population.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=10 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=8 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=6 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MSSA in Lesion Sample Microbiological Success, Presumed Eradication	10 Number of pathogens	7 Number of pathogens	4 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MSSA in Lesion Sample Microbiological Failure, Presumed Recurrence	0 Number of pathogens	1 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for MSSA in Lesion Sample Microbiological Failure, Unable to Determine	0 Number of pathogens	0 Number of pathogens	2 Number of pathogens

SECONDARY outcome

Timeframe: Day 21 to Day 28

Population: Modified Microbiological ITT population.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=4 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=4 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=3 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Success, Presumed Eradication	3 Number of pathogens	2 Number of pathogens	2 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Presumed Recurrence	0 Number of pathogens	1 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for Other Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Unable to Determine	1 Number of pathogens	1 Number of pathogens	1 Number of pathogens

SECONDARY outcome

Timeframe: Day 21 to Day 28

Population: Modified Microbiological ITT population.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=40 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=29 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=13 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Success, Eradication	1 Number of pathogens	0 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Success, Presumed Eradication	36 Number of pathogens	23 Number of pathogens	10 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Presumed Recurrence	1 Number of pathogens	5 Number of pathogens	0 Number of pathogens
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for All Gram-positive Aerobic Pathogens in Lesion Sample Microbiological Failure, Unable to Determine	5 Number of pathogens	4 Number of pathogens	4 Number of pathogens

SECONDARY outcome

Timeframe: Day 21 to Day 28

Population: Modified Microbiological ITT population.

Microbiological outcome was determined by comparing Baseline blood culture, to culture results at final follow up visit. Corresponding response (success or failure) was then assigned. Microbiological eradication was culture documented elimination of Baseline pathogens from a bacteriology specimen taken at final follow up visit. Presumed microbiological eradication was when there was a clinical success and no bacteriological specimen was obtained at final follow up visit. Culture documented presence of Baseline pathogens in a bacteriology specimen taken at final follow up visit was microbiological recurrence. Presumed microbiological recurrence was when there was a clinical failure and no bacteriological specimen was obtained at final follow up visit. When the determination of Baseline pathogen response could not be made, the outcome was unable to determine. Data for SA, MRSA and all Gram-positive aerobic pathogens in lesion sample has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=2 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample SA, Microbiological Success, Presumed Eradication	2 Number of pathogens	—	—
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample MRSA,Microbiological Success,Presumed Eradication	2 Number of pathogens	—	—
Number of Pathogens With Microbiological Response and Outcome at Follow up Visit for SA, MRSA and All Gram-positive Aerobic Pathogens in Blood Sample Aerobic,MicrobiologicalSuccess,PresumedEradication	2 Number of pathogens	—	—

SECONDARY outcome

Timeframe: Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3

Population: PK Parameter Population consisted of all participants in the PK concentration population for whom valid and evaluable PK parameters were derived. Only those participants available at the indicated time points were analyzed.

Samples for assessment of PK parameter Cmax was done on at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The first occurrence of the Cmax was determined directly from the raw concentration-time data. Data for participants while on IV therapy has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=50 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=33 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=24 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Pharmacokinetic (PK) Parameters (From GSK2140944 Plasma Concentration-time Data): Maximum Observed Concentration (Cmax) on IV Therapy	4590 Nanograms per milliliter Geometric Coefficient of Variation 42.4	6059 Nanograms per milliliter Geometric Coefficient of Variation 29.8	8848 Nanograms per milliliter Geometric Coefficient of Variation 105.5

SECONDARY outcome

Timeframe: Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)

Population: PK Parameter Population. Only those participants available at the indicated time points were analyzed.

Samples for assessment of PK parameter Cmax was done at Predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The first occurrence of the Cmax was determined directly from the raw concentration-time data. Data for participants while on oral dose therapy has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=51 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=33 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=24 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Cmax on Oral Dose Therapy	2342 Nanograms per milliliter Geometric Coefficient of Variation 84.7	4329 Nanograms per milliliter Geometric Coefficient of Variation 67.8	3858 Nanograms per milliliter Geometric Coefficient of Variation 94.1

SECONDARY outcome

Timeframe: Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3

Population: PK Parameter Population. Only those participants available at the indicated time points were analyzed.

Samples for assessment of PK parameter tmax was done at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The time at which Cmax was observed was determined directly from the raw concentration-time data. Data for participants while on IV therapy has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=50 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=33 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=24 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Time to Cmax (Tmax) on IV Therapy	1.95 Hours Interval 0.0 to 3.05	1.90 Hours Interval 0.9 to 3.0	1.93 Hours Interval 0.0 to 3.0

SECONDARY outcome

Timeframe: Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)

Population: PK Parameter Population. Only those participants available at the indicated time points were analyzed.

Samples for assessment of PK parameter tmax was done at Predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The time at which Cmax was observed was determined directly from the raw concentration-time data. Data for participants while on oral dose therapy has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=51 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=33 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=24 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Tmax on Oral Dose Therapy	3.00 Hours Interval 0.95 to 12.0	2.92 Hours Interval 1.02 to 12.0	2.98 Hours Interval 0.98 to 8.0

SECONDARY outcome

Timeframe: Predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3

Population: PK Parameter Population. Only those participants available at the indicated time points were analyzed.

Samples for assessment of PK parameters AUClast and AUC0-tau was done at predose, 1, 2, 2.5, 3, 6, 12 hours post dose on Day 1 to 3. The AUC 0-t and AUC0-tau was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Data for participants while on IV therapy has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=54 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=36 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=24 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Time of the Last Quantifiable Concentration [AUC (0-t)] and AUC Over the Dosing Interval [AUC(0-tau)] on IV Therapy AUClast	15992 Hour nanograms per milliliter Geometric Coefficient of Variation 36.7	20904 Hour nanograms per milliliter Geometric Coefficient of Variation 31.8	20851 Hour nanograms per milliliter Geometric Coefficient of Variation 64.8
PK Parameters (From GSK2140944 Plasma Concentration-time Data): Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Time of the Last Quantifiable Concentration [AUC (0-t)] and AUC Over the Dosing Interval [AUC(0-tau)] on IV Therapy AUC0-tau	16159 Hour nanograms per milliliter Geometric Coefficient of Variation 36.3	20815 Hour nanograms per milliliter Geometric Coefficient of Variation 31.7	21499 Hour nanograms per milliliter Geometric Coefficient of Variation 66.9

SECONDARY outcome

Timeframe: Predose, 1, 2, 3 hours after first orally administered drug and Day 7 to 10 (predose)

Population: PK Parameter Population. Only those participants available at the indicated time points were analyzed.

Samples for assessment of PK parameters AUClast and AUC0-tau was done at predose, 1, 2, 3 hours after first orally administered drug and one predose time point anytime from Day 7 to 10. The AUC 0-t and AUC0-tau was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Data for participants while on oral dose therapy has been presented.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=51 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=34 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
PK Parameters (From GSK2140944 Plasma Concentration-time Data): AUC (0-t) and AUC(0-tau) on Oral Dose Therapy AUClast	11965 Hour nanograms per milliliter Geometric Coefficient of Variation 101.7	19308 Hour nanograms per milliliter Geometric Coefficient of Variation 98.8	15923 Hour nanograms per milliliter Geometric Coefficient of Variation 117.4
PK Parameters (From GSK2140944 Plasma Concentration-time Data): AUC (0-t) and AUC(0-tau) on Oral Dose Therapy AUC0-tau	14404 Hour nanograms per milliliter Geometric Coefficient of Variation 78.2	24253 Hour nanograms per milliliter Geometric Coefficient of Variation 65.4	19300 Hour nanograms per milliliter Geometric Coefficient of Variation 77.9

SECONDARY outcome

Timeframe: Up to Day 28

Population: Modified MITT Population.

Reduction in susceptibility was defined as a \>=4-fold increase in minimum inhibitory concentration (MIC) or \>=6 millimeter decrease in zone size between an isolate obtained at Baseline and the same pathogen at subsequent visits.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=40 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=29 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=13 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Participants Demonstrating a Decrease in GSK2140944 Susceptibility When Comparing Isolates Recovered From Baseline With Those From Any Time Post-Baseline Skin Specimens	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to Day 28

Population: Safety population comprised the same set of participants from MITT population and received at least one dose of study medication.

An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, medically significant or all events of possible drug-induced liver injury with hyperbilirubinemia.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Any SAEs	1 Participants	1 Participants	0 Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Any AEs	41 Participants	25 Participants	18 Participants

SECONDARY outcome

Timeframe: Baseline (Day 1) up to Day 28

Population: Safety population. Data for only those participants available at the indicated time points were collected and analyzed. Data points with null value for participants analyzed indicate data not collected for respective category and treatment arm.

SBP and DBP was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day 1) up to Day 28

Pulse rate was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Change From Baseline in Pulse Rate ON IV TREATMENT/DAY 1	-4.5 Beats per minute Standard Deviation 11.38	-3.8 Beats per minute Standard Deviation 10.66	-2.0 Beats per minute Standard Deviation 10.39
Change From Baseline in Pulse Rate ON IV TREATMENT/DAY 2	-6.3 Beats per minute Standard Deviation 14.31	-1.2 Beats per minute Standard Deviation 10.66	-5.2 Beats per minute Standard Deviation 10.78
Change From Baseline in Pulse Rate ON IV TREATMENT/DAY 3	-7.5 Beats per minute Standard Deviation 14.08	-6.6 Beats per minute Standard Deviation 10.28	-7.1 Beats per minute Standard Deviation 12.62
Change From Baseline in Pulse Rate ON IV TREATMENT/DAY 4	-11.3 Beats per minute Standard Deviation 18.27	-5.5 Beats per minute Standard Deviation 10.37	-7.0 Beats per minute Standard Deviation 12.73
Change From Baseline in Pulse Rate ON IV TREATMENT/DAY 5	-15.1 Beats per minute Standard Deviation 22.36	-9.9 Beats per minute Standard Deviation 13.50	—
Change From Baseline in Pulse Rate ON IV TREATMENT/DAY 6	-16.9 Beats per minute Standard Deviation 21.60	-11.0 Beats per minute Standard Deviation 10.22	—
Change From Baseline in Pulse Rate ON IV TREATMENT/DAY 7	-28.4 Beats per minute Standard Deviation 33.57	-18.0 Beats per minute Standard Deviation 16.75	—
Change From Baseline in Pulse Rate ON IV TREATMENT/DAY 8	-32.3 Beats per minute Standard Deviation 15.63	—	—
Change From Baseline in Pulse Rate ON IV TREATMENT/DAY 9	-45.5 Beats per minute Standard Deviation 31.82	—	—
Change From Baseline in Pulse Rate ON IV TREATMENT/DAY 10	-68.0 Beats per minute Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Pulse Rate ORAL - FIRST DAY	-6.7 Beats per minute Standard Deviation 15.43	-5.6 Beats per minute Standard Deviation 13.47	-7.0 Beats per minute Standard Deviation 11.45
Change From Baseline in Pulse Rate ORAL - DAY 7-10	-1.6 Beats per minute Standard Deviation 12.35	-1.8 Beats per minute Standard Deviation 10.53	-5.7 Beats per minute Standard Deviation 15.33
Change From Baseline in Pulse Rate POST THERAPY DAY 12-18	-1.6 Beats per minute Standard Deviation 15.02	2.7 Beats per minute Standard Deviation 13.38	-7.0 Beats per minute Standard Deviation 16.34
Change From Baseline in Pulse Rate FOLLOW UP DAY 21-28	-1.6 Beats per minute Standard Deviation 13.59	-1.1 Beats per minute Standard Deviation 10.09	-2.5 Beats per minute Standard Deviation 17.10
Change From Baseline in Pulse Rate POST DOSE DAY 3-10	-15.0 Beats per minute Standard Deviation NA Only one participant was analyzed.	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1) up to Day 28

Respiratory rate was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day 1) up to Day 28

Body temperature was measured with the participant in a supine or semi-supine position, having rested in that position for at least 10 minutes. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Change From Baseline in Vital Sign: Body Temperature ON IV TREATMENT/DAY 1	-0.126 Celcius Standard Deviation 0.6632	-0.053 Celcius Standard Deviation 0.4114	-0.172 Celcius Standard Deviation 0.4208
Change From Baseline in Vital Sign: Body Temperature ON IV TREATMENT/DAY 2	-0.195 Celcius Standard Deviation 0.6058	-0.173 Celcius Standard Deviation 0.4642	-0.400 Celcius Standard Deviation 0.5672
Change From Baseline in Vital Sign: Body Temperature ON IV TREATMENT/DAY 3	-0.393 Celcius Standard Deviation 0.5986	-0.308 Celcius Standard Deviation 0.4216	-0.456 Celcius Standard Deviation 0.7548
Change From Baseline in Vital Sign: Body Temperature ON IV TREATMENT/DAY 4	-0.476 Celcius Standard Deviation 0.7242	-0.455 Celcius Standard Deviation 0.5610	-0.550 Celcius Standard Deviation 0.2121
Change From Baseline in Vital Sign: Body Temperature ON IV TREATMENT/DAY 5	-0.662 Celcius Standard Deviation 0.8412	-0.521 Celcius Standard Deviation 0.6013	—
Change From Baseline in Vital Sign: Body Temperature ON IV TREATMENT/DAY 6	-1.080 Celcius Standard Deviation 0.9589	-0.842 Celcius Standard Deviation 1.0670	—
Change From Baseline in Vital Sign: Body Temperature ON IV TREATMENT/DAY 7	-1.400 Celcius Standard Deviation 1.1726	-0.738 Celcius Standard Deviation 0.8901	—
Change From Baseline in Vital Sign: Body Temperature ON IV TREATMENT/DAY 8	-0.533 Celcius Standard Deviation 0.6110	—	—
Change From Baseline in Vital Sign: Body Temperature ON IV TREATMENT/DAY 9	-0.800 Celcius Standard Deviation 0.7071	—	—
Change From Baseline in Vital Sign: Body Temperature ON IV TREATMENT/DAY 10	-1.100 Celcius Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Vital Sign: Body Temperature ORAL - FIRST DAY	-0.398 Celcius Standard Deviation 0.8149	-0.304 Celcius Standard Deviation 0.7005	-0.608 Celcius Standard Deviation 0.7593
Change From Baseline in Vital Sign: Body Temperature ORAL - DAY 7-10	-0.498 Celcius Standard Deviation 0.6496	-0.468 Celcius Standard Deviation 0.6417	-0.635 Celcius Standard Deviation 0.8483
Change From Baseline in Vital Sign: Body Temperature POST THERAPY DAY 12-18	-0.485 Celcius Standard Deviation 0.7579	-0.439 Celcius Standard Deviation 0.6764	-0.645 Celcius Standard Deviation 0.9379
Change From Baseline in Vital Sign: Body Temperature FOLLOW UP DAY 21-28	-0.441 Celcius Standard Deviation 0.7579	-0.375 Celcius Standard Deviation 0.7255	-0.604 Celcius Standard Deviation 0.8891
Change From Baseline in Vital Sign: Body Temperature POST DOSE DAY 3-10	-0.200 Celcius Standard Deviation NA Only one participant was analyzed.	—	—

SECONDARY outcome

Timeframe: Up to Day 28

Population: Safety Population. Only those participants available at the indicated time points were analyzed.

The 12-lead ECGs was obtained at Day 1, Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28 for corrected QT, using Fridericia formula (QTcF), corrected QT using Bazett's formula (QTcB) and QRS intervals. The number of participants with maximum post-baseline ECG value exceeding the following limits have been reported: QTcB/QTcF interval \> 450 and ≤ 480 millisecond (msec), QTcB/QTcF interval \> 480 and ≤ 500 msec, QTcB/QTcF interval \> 500 msec, QRS interval \< 70 msec and QRS interval \> 120 msec.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=38 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings QTcB, Maximum Post-Baseline, <=450	27 Participants	15 Participants	9 Participants
Number of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings QTcB, Maximum Post-Baseline, <=450 and <=480	28 Participants	19 Participants	11 Participants
Number of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings QTcB, Maximum Post-Baseline, >480 and <=500	3 Participants	4 Participants	3 Participants
Number of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings QTcB, Maximum Post-Baseline, >500	0 Participants	0 Participants	2 Participants
Number of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings QTcF, Maximum Post-Baseline, <=450	47 Participants	28 Participants	17 Participants
Number of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings QTcF, Maximum Post-Baseline, <=450 and <=480	11 Participants	10 Participants	8 Participants
Number of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings QRS, Maximum Post-Baseline, 70 - 120	56 Participants	36 Participants	23 Participants
Number of Participants With Maximum Post-Baseline Electrocardiogram (ECG) Readings QRS, Maximum Post-Baseline, >120	2 Participants	2 Participants	2 Participants

SECONDARY outcome

Timeframe: Baseline (Day 1) up to Day 28

Blood samples for assessment of clinical chemistry parameters of ALT, ALP, AST, FSH and GGT was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day 1) up to Day 28

Blood samples for assessment of clinical chemistry parameters of albumin and total protein was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Protein, ON IV TREATMENT/DAY 5	-0.5 Gram per liter Standard Deviation 8.22	-2.3 Gram per liter Standard Deviation 7.34	—
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Protein, ON IV TREATMENT/DAY 7	5.5 Gram per liter Standard Deviation 13.44	-1.0 Gram per liter Standard Deviation 8.49	—
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Protein, ORAL - FIRST DAY	1.4 Gram per liter Standard Deviation 5.96	-0.2 Gram per liter Standard Deviation 6.82	-1.2 Gram per liter Standard Deviation 5.05
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Protein, ORAL - DAY 7-10	3.1 Gram per liter Standard Deviation 6.95	2.2 Gram per liter Standard Deviation 5.88	0.5 Gram per liter Standard Deviation 3.59
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Protein, POST THERAPY DAY 12-18	2.9 Gram per liter Standard Deviation 7.21	3.1 Gram per liter Standard Deviation 9.14	-1.1 Gram per liter Standard Deviation 5.93
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Protein, FOLLOW UP DAY 21-28	5.0 Gram per liter Standard Deviation 5.29	0.8 Gram per liter Standard Deviation 5.06	-7.0 Gram per liter Standard Deviation NA Only one participant was analyzed.
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Protein, POST DOSE DAY 3-10	-3.0 Gram per liter Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Albumin, ON IV TREATMENT/DAY 2	-2.4 Gram per liter Standard Deviation 3.57	-1.1 Gram per liter Standard Deviation 2.93	-2.9 Gram per liter Standard Deviation 3.34
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Albumin, ON IV TREATMENT/DAY 3	-1.7 Gram per liter Standard Deviation 4.09	-0.6 Gram per liter Standard Deviation 3.52	-2.0 Gram per liter Standard Deviation 3.46
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Albumin, ON IV TREATMENT/DAY 5	-1.1 Gram per liter Standard Deviation 4.09	-1.5 Gram per liter Standard Deviation 3.62	—
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Albumin, ON IV TREATMENT/DAY 7	4.0 Gram per liter Standard Deviation 8.49	-0.5 Gram per liter Standard Deviation 0.71	—
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Albumin, ORAL - FIRST DAY	0.0 Gram per liter Standard Deviation 3.39	-0.2 Gram per liter Standard Deviation 3.37	-0.9 Gram per liter Standard Deviation 2.86
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Albumin, ORAL - DAY 7-10	1.8 Gram per liter Standard Deviation 3.58	1.4 Gram per liter Standard Deviation 3.04	1.2 Gram per liter Standard Deviation 2.51
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Albumin, POST THERAPY DAY 12-18	2.1 Gram per liter Standard Deviation 3.81	2.8 Gram per liter Standard Deviation 4.41	0.8 Gram per liter Standard Deviation 3.61
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Albumin, FOLLOW UP DAY 21-28	2.8 Gram per liter Standard Deviation 2.36	0.3 Gram per liter Standard Deviation 2.22	0.0 Gram per liter Standard Deviation NA Only one participant was analyzed.
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Albumin, POST DOSE DAY 3-10	-4.0 Gram per liter Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Protein, ON IV TREATMENT/DAY 2	-3.2 Gram per liter Standard Deviation 6.36	-1.9 Gram per liter Standard Deviation 5.86	-5.2 Gram per liter Standard Deviation 6.28
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Protein, ON IV TREATMENT/DAY 3	-1.6 Gram per liter Standard Deviation 7.04	-0.3 Gram per liter Standard Deviation 5.88	-4.8 Gram per liter Standard Deviation 6.59
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Protein, ON IV TREATMENT/DAY 4	—	0.0 Gram per liter Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein Albumin, ON IV TREATMENT/DAY 4	—	1.0 Gram per liter Standard Deviation NA Only one participant was analyzed.	—

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated POST THERAPY DAY 12-18	-8.8 Milliliter per minute Standard Deviation 28.55	-10.4 Milliliter per minute Standard Deviation 24.61	-5.6 Milliliter per minute Standard Deviation 12.72
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated ON IV TREATMENT/DAY 2	-6.8 Milliliter per minute Standard Deviation 22.65	-1.8 Milliliter per minute Standard Deviation 17.47	-1.7 Milliliter per minute Standard Deviation 17.98
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated ON IV TREATMENT/DAY 3	-4.8 Milliliter per minute Standard Deviation 32.17	1.7 Milliliter per minute Standard Deviation 30.02	3.8 Milliliter per minute Standard Deviation 19.70
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated ON IV TREATMENT/DAY 4	—	5.0 Milliliter per minute Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated ON IV TREATMENT/DAY 5	-17.4 Milliliter per minute Standard Deviation 59.39	-14.5 Milliliter per minute Standard Deviation 14.92	—
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated ON IV TREATMENT/DAY 7	-22.0 Milliliter per minute Standard Deviation 29.70	-9.5 Milliliter per minute Standard Deviation 13.44	—
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated ORAL - DAY 7-10	-13.2 Milliliter per minute Standard Deviation 29.04	-9.7 Milliliter per minute Standard Deviation 36.67	-8.3 Milliliter per minute Standard Deviation 16.53
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated ORAL - FIRST DAY	-12.6 Milliliter per minute Standard Deviation 32.53	-1.1 Milliliter per minute Standard Deviation 31.43	-6.3 Milliliter per minute Standard Deviation 16.45
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated FOLLOW UP DAY 21-28	-13.7 Milliliter per minute Standard Deviation 25.54	3.8 Milliliter per minute Standard Deviation 5.74	—
Change From Baseline in Clinical Chemistry Parameters: Creatinine Clearance, Estimated POST DOSE DAY 3-10	6.0 Milliliter per minute Standard Deviation NA Only one participant was analyzed.	—	—

SECONDARY outcome

Timeframe: Baseline (Day 1)

Population: Safety Population. Only those participants available at the indicated time points were analyzed.

Blood samples for assessment of clinical chemistry parameter of estradiol was collected at Baseline (Day 1). No post-baseline values were reported.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=10 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=4 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=2 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Estradiol Values at Baseline	229.4 Picomole per liter Standard Deviation 196.66	148.8 Picomole per liter Standard Deviation 153.58	23.5 Picomole per liter Standard Deviation 23.33

SECONDARY outcome

Timeframe: Baseline (Day 1) up to Day 28

Blood samples for assessment of hematology parameters of basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the post-Baseline value from Baseline value.

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Change From Baseline in Hematology Parameters: Hematocrit ON IV TREATMENT/DAY 2	-0.0111 Ratio Standard Deviation 0.03004	-0.0065 Ratio Standard Deviation 0.03316	-0.0125 Ratio Standard Deviation 0.03152
Change From Baseline in Hematology Parameters: Hematocrit ON IV TREATMENT/DAY 3	-0.0066 Ratio Standard Deviation 0.03683	-0.0099 Ratio Standard Deviation 0.03922	-0.0073 Ratio Standard Deviation 0.02536
Change From Baseline in Hematology Parameters: Hematocrit ON IV TREATMENT/DAY 4	—	-0.0260 Ratio Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Hematology Parameters: Hematocrit ON IV TREATMENT/DAY 5	-0.0101 Ratio Standard Deviation 0.03166	-0.0322 Ratio Standard Deviation 0.04462	—
Change From Baseline in Hematology Parameters: Hematocrit ON IV TREATMENT/DAY 7	-0.0353 Ratio Standard Deviation 0.01873	0.0020 Ratio Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Hematology Parameters: Hematocrit ON IV TREATMENT/DAY 10	-0.0690 Ratio Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Hematology Parameters: Hematocrit ORAL - FIRST DAY	0.0112 Ratio Standard Deviation 0.03422	-0.0041 Ratio Standard Deviation 0.04091	-0.0043 Ratio Standard Deviation 0.02854
Change From Baseline in Hematology Parameters: Hematocrit ORAL - DAY 7-10	0.0080 Ratio Standard Deviation 0.03674	0.0027 Ratio Standard Deviation 0.03459	-0.0040 Ratio Standard Deviation 0.02840
Change From Baseline in Hematology Parameters: Hematocrit POST THERAPY DAY 12-18	0.0100 Ratio Standard Deviation 0.03340	0.0039 Ratio Standard Deviation 0.02846	-0.0006 Ratio Standard Deviation 0.04085
Change From Baseline in Hematology Parameters: Hematocrit FOLLOW UP DAY 21-28	0.0178 Ratio Standard Deviation 0.01699	-0.0220 Ratio Standard Deviation NA Only one participant was analyzed.	0.0033 Ratio Standard Deviation 0.03988
Change From Baseline in Hematology Parameters: Hematocrit POST DOSE DAY 3-10	-0.0320 Ratio Standard Deviation NA Only one participant was analyzed.	—	—

SECONDARY outcome

Timeframe: Up to day 28

Population: Safety Population. Only those participants available at the indicated time points were analyzed.

Samples for urinalysis assessment was collected at Baseline (Day 1), Day 2, Day 7 to 10, Day 12 to 21 and Day 21 to Day 28 for Glucose, Ketones, Occult Blood, Protein and pH. Participants with abnormal urinalysis result was reported.

Outcome measures

Outcome measures
Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Number of Participants With Abnormal Urinalysis Dipstick Results pH, Post-Baseline Maximum, 8.5	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, BASELINE/DAY 1, Trace	1 Participants	2 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, BASELINE/DAY 1, 1+	1 Participants	1 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, BASELINE/DAY 1, 3+	1 Participants	2 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ON IV TREATMENT/DAY 2, Trace	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ON IV TREATMENT/DAY 2, 1+	0 Participants	0 Participants	2 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ON IV TREATMENT/DAY 2, 3+	3 Participants	2 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ON IV TREATMENT/DAY 3, 2+	1 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ON IV TREATMENT/DAY 3, 3+	1 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ON IV TREATMENT/DAY 5, 2+	1 Participants	0 Participants	—
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ON IV TREATMENT/DAY 7, 2+	1 Participants	0 Participants	—
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ORAL - FIRST DAY, Trace	0 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ORAL - FIRST DAY, 1+	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ORAL - FIRST DAY, 3+	1 Participants	2 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ORAL - DAY 7-10, Trace	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ORAL - DAY 7-10, 1+	0 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ORAL - DAY 7-10, 2+	0 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, ORAL - DAY 7-10, 3+	0 Participants	2 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, POST THERAPY DAY 12-18, Trace	3 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, POST THERAPY DAY 12-18, 1+	0 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Glucose, POST THERAPY DAY 12-18, 3+	0 Participants	3 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Ketones, BASELINE/DAY 1, Trace	8 Participants	3 Participants	6 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Ketones, BASELINE/DAY 1, 1+	1 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Ketones, BASELINE/DAY 1, 3+	0 Participants	2 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Ketones, ON IV TREATMENT/DAY 2, Trace	4 Participants	3 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Ketones, ON IV TREATMENT/DAY 2, 1+	2 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Ketones, ON IV TREATMENT/DAY 2, 3+	0 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Ketones, ON IV TREATMENT/DAY 3, Trace	5 Participants	0 Participants	2 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Ketones, ORAL - FIRST DAY, Trace	3 Participants	1 Participants	2 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Ketones, ORAL - FIRST DAY, 2+	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Ketones, ORAL - DAY 7-10, Trace	6 Participants	3 Participants	3 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Ketones, POST THERAPY DAY 12-18, Trace	8 Participants	6 Participants	2 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, BASELINE/DAY 1, Trace	3 Participants	1 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, BASELINE/DAY 1, 1+	4 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, BASELINE/DAY 1, 2+	1 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, BASELINE/DAY 1, 3+	4 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ON IV TREATMENT/DAY 2, Trace	3 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ON IV TREATMENT/DAY 2, 1+	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ON IV TREATMENT/DAY 2, 2+	0 Participants	0 Participants	2 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ON IV TREATMENT/DAY 2, 3+	1 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ON IV TREATMENT/DAY 3, Trace	0 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ON IV TREATMENT/DAY 3, 3+	0 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ON IV TREATMENT/DAY 5, Trace	2 Participants	0 Participants	—
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ON IV TREATMENT/DAY 7, Trace	1 Participants	0 Participants	—
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ORAL - FIRST DAY, Trace	2 Participants	1 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ORAL - FIRST DAY, 1+	3 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ORAL - FIRST DAY, 2+	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ORAL - FIRST DAY, 3+	0 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ORAL - DAY 7-10, Trace	1 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ORAL - DAY 7-10, 2+	1 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, ORAL - DAY 7-10, 3+	0 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, POST THERAPY DAY 12-18, Trace	1 Participants	1 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, POST THERAPY DAY 12-18, 1+	1 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, POST THERAPY DAY 12-18, 2+	1 Participants	1 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Occult Blood, POST THERAPY DAY 12-18, 3+	1 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, BASELINE/DAY 1, Trace	7 Participants	5 Participants	5 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, BASELINE/DAY 1, 1+	6 Participants	4 Participants	5 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, BASELINE/DAY 1, 2+	1 Participants	0 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, BASELINE/DAY 1, 3+	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ON IV TREATMENT/DAY 2, Trace	4 Participants	6 Participants	4 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ON IV TREATMENT/DAY 2, 1+	7 Participants	7 Participants	4 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ON IV TREATMENT/DAY 3, Trace	4 Participants	3 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ON IV TREATMENT/DAY 3, 1+	3 Participants	2 Participants	3 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ON IV TREATMENT/DAY 3, 2+	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ON IV TREATMENT/DAY 5, Trace	2 Participants	0 Participants	—
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ON IV TREATMENT/DAY 5, 1+	0 Participants	1 Participants	—
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ORAL - FIRST DAY, Trace	2 Participants	3 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ORAL - FIRST DAY, 1+	0 Participants	4 Participants	2 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ORAL - FIRST DAY, 2+	1 Participants	0 Participants	0 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ORAL - DAY 7-10, Trace	7 Participants	4 Participants	6 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ORAL - DAY 7-10, 1+	6 Participants	5 Participants	4 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, ORAL - DAY 7-10, 2+	1 Participants	1 Participants	1 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, POST THERAPY DAY 12-18, Trace	8 Participants	6 Participants	2 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, POST THERAPY DAY 12-18, 1+	3 Participants	4 Participants	3 Participants
Number of Participants With Abnormal Urinalysis Dipstick Results Protein, POST THERAPY DAY 12-18, 2+	0 Participants	1 Participants	0 Participants

Adverse Events

Gepotidacin 750 mg q12h

Serious events: 1 serious events

Other events: 30 other events

Deaths: 0 deaths

Gepotidacin 1000 mg q12h

Serious events: 1 serious events

Other events: 20 other events

Deaths: 1 deaths

Gepotidacin 1000 mg q8h

Serious events: 0 serious events

Other events: 14 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Gepotidacin 750 mg q12h n=58 participants at risk Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 participants at risk Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 participants at risk Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Infections and infestations Cellulitis	1.7% 1/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	0.00% 0/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	0.00% 0/25 • AEs were collected up to follow-up (Day 28). Safety population was used.
Infections and infestations Septic shock	0.00% 0/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	2.6% 1/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	0.00% 0/25 • AEs were collected up to follow-up (Day 28). Safety population was used.

Other adverse events

Other adverse events
Measure	Gepotidacin 750 mg q12h n=58 participants at risk Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 participants at risk Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 participants at risk Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Gastrointestinal disorders Nausea	20.7% 12/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	23.1% 9/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	16.0% 4/25 • AEs were collected up to follow-up (Day 28). Safety population was used.
Gastrointestinal disorders Diarrhoea	8.6% 5/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	15.4% 6/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	20.0% 5/25 • AEs were collected up to follow-up (Day 28). Safety population was used.
Gastrointestinal disorders Vomiting	5.2% 3/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	5.1% 2/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	12.0% 3/25 • AEs were collected up to follow-up (Day 28). Safety population was used.
Gastrointestinal disorders Flatulence	5.2% 3/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	2.6% 1/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	8.0% 2/25 • AEs were collected up to follow-up (Day 28). Safety population was used.
Gastrointestinal disorders Gastrooesophageal reflux disease	1.7% 1/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	0.00% 0/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	8.0% 2/25 • AEs were collected up to follow-up (Day 28). Safety population was used.
Investigations Alanine aminotransferase increased	6.9% 4/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	7.7% 3/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	8.0% 2/25 • AEs were collected up to follow-up (Day 28). Safety population was used.
Investigations Aspartate aminotransferase increased	5.2% 3/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	7.7% 3/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	4.0% 1/25 • AEs were collected up to follow-up (Day 28). Safety population was used.
Investigations Gamma-glutamyltransferase increased	5.2% 3/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	7.7% 3/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	0.00% 0/25 • AEs were collected up to follow-up (Day 28). Safety population was used.
Nervous system disorders Headache	10.3% 6/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	2.6% 1/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	0.00% 0/25 • AEs were collected up to follow-up (Day 28). Safety population was used.
General disorders Infusion site extravasation	5.2% 3/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	2.6% 1/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	0.00% 0/25 • AEs were collected up to follow-up (Day 28). Safety population was used.
Skin and subcutaneous tissue disorders Pruritus generalised	1.7% 1/58 • AEs were collected up to follow-up (Day 28). Safety population was used.	7.7% 3/39 • AEs were collected up to follow-up (Day 28). Safety population was used.	0.00% 0/25 • AEs were collected up to follow-up (Day 28). Safety population was used.

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER

Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, POST THERAPY DAY 12-18	-0.1 Millimeters of mercury Standard Deviation 13.71	4.5 Millimeters of mercury Standard Deviation 11.33	4.1 Millimeters of mercury Standard Deviation 11.09
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ORAL - DAY 7-10	-1.2 Millimeters of mercury Standard Deviation 9.12	0.4 Millimeters of mercury Standard Deviation 8.13	0.0 Millimeters of mercury Standard Deviation 11.13
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, POST THERAPY DAY 12-18	2.2 Millimeters of mercury Standard Deviation 9.18	2.3 Millimeters of mercury Standard Deviation 8.00	3.5 Millimeters of mercury Standard Deviation 12.23
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, FOLLOW UP DAY 21-28	2.3 Millimeters of mercury Standard Deviation 11.00	0.0 Millimeters of mercury Standard Deviation 9.94	1.2 Millimeters of mercury Standard Deviation 13.44
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, POST DOSE DAY 3-10	-5.0 Millimeters of mercury Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ON IV TREATMENT/DAY 7	-1.6 Millimeters of mercury Standard Deviation 23.37	-13.8 Millimeters of mercury Standard Deviation 19.09	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, FOLLOW UP DAY 21-28	2.5 Millimeters of mercury Standard Deviation 12.87	2.1 Millimeters of mercury Standard Deviation 12.24	1.7 Millimeters of mercury Standard Deviation 15.60
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ON IV TREATMENT/DAY 1	-2.9 Millimeters of mercury Standard Deviation 15.07	-1.7 Millimeters of mercury Standard Deviation 13.90	-2.4 Millimeters of mercury Standard Deviation 9.43
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ON IV TREATMENT/DAY 2	-4.8 Millimeters of mercury Standard Deviation 14.63	0.3 Millimeters of mercury Standard Deviation 13.55	-1.9 Millimeters of mercury Standard Deviation 9.73
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ON IV TREATMENT/DAY 3	-1.7 Millimeters of mercury Standard Deviation 14.57	1.6 Millimeters of mercury Standard Deviation 11.25	-2.1 Millimeters of mercury Standard Deviation 13.88
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ON IV TREATMENT/DAY 4	-3.2 Millimeters of mercury Standard Deviation 14.25	-1.2 Millimeters of mercury Standard Deviation 17.11	-22.0 Millimeters of mercury Standard Deviation 31.11
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ON IV TREATMENT/DAY 5	-4.8 Millimeters of mercury Standard Deviation 17.90	-1.6 Millimeters of mercury Standard Deviation 31.01	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ON IV TREATMENT/DAY 6	-8.0 Millimeters of mercury Standard Deviation 14.60	-2.7 Millimeters of mercury Standard Deviation 14.83	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ON IV TREATMENT/DAY 7	-17.0 Millimeters of mercury Standard Deviation 16.57	2.3 Millimeters of mercury Standard Deviation 32.39	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ON IV TREATMENT/DAY 8	-10.3 Millimeters of mercury Standard Deviation 29.87	—	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ON IV TREATMENT/DAY 9	12.0 Millimeters of mercury Standard Deviation 1.41	—	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ON IV TREATMENT/DAY 10	6.0 Millimeters of mercury Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ORAL - FIRST DAY	1.6 Millimeters of mercury Standard Deviation 13.36	2.3 Millimeters of mercury Standard Deviation 13.86	-3.7 Millimeters of mercury Standard Deviation 13.59
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, ORAL - DAY 7-10	2.8 Millimeters of mercury Standard Deviation 9.14	1.9 Millimeters of mercury Standard Deviation 10.55	-0.9 Millimeters of mercury Standard Deviation 17.91
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, POST DOSE DAY 3-10	-23.0 Millimeters of mercury Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ON IV TREATMENT/DAY 1	-3.1 Millimeters of mercury Standard Deviation 10.28	-2.9 Millimeters of mercury Standard Deviation 10.97	-2.3 Millimeters of mercury Standard Deviation 9.21
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ON IV TREATMENT/DAY 2	-3.5 Millimeters of mercury Standard Deviation 10.84	-0.9 Millimeters of mercury Standard Deviation 9.26	-2.1 Millimeters of mercury Standard Deviation 9.77
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ON IV TREATMENT/DAY 3	-4.5 Millimeters of mercury Standard Deviation 10.98	-0.9 Millimeters of mercury Standard Deviation 9.93	-3.5 Millimeters of mercury Standard Deviation 14.74
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ON IV TREATMENT/DAY 4	-1.9 Millimeters of mercury Standard Deviation 12.19	0.6 Millimeters of mercury Standard Deviation 11.19	-12.5 Millimeters of mercury Standard Deviation 30.41
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ON IV TREATMENT/DAY 5	-0.9 Millimeters of mercury Standard Deviation 13.66	-2.0 Millimeters of mercury Standard Deviation 14.83	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ON IV TREATMENT/DAY 6	-1.4 Millimeters of mercury Standard Deviation 11.75	-9.2 Millimeters of mercury Standard Deviation 15.38	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ON IV TREATMENT/DAY 8	-0.3 Millimeters of mercury Standard Deviation 18.50	—	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ON IV TREATMENT/DAY 9	13.0 Millimeters of mercury Standard Deviation 21.21	—	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ON IV TREATMENT/DAY 10	8.0 Millimeters of mercury Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, ORAL - FIRST DAY	0.0 Millimeters of mercury Standard Deviation 11.26	-1.0 Millimeters of mercury Standard Deviation 8.44	-3.4 Millimeters of mercury Standard Deviation 12.84

Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Change From Baseline in Respiratory Rate ON IV TREATMENT/DAY 1	-0.4 Breaths per minute Standard Deviation 2.66	-0.1 Breaths per minute Standard Deviation 1.64	0.7 Breaths per minute Standard Deviation 2.90
Change From Baseline in Respiratory Rate ON IV TREATMENT/DAY 2	0.1 Breaths per minute Standard Deviation 2.28	-0.3 Breaths per minute Standard Deviation 2.37	-0.5 Breaths per minute Standard Deviation 1.73
Change From Baseline in Respiratory Rate ON IV TREATMENT/DAY 3	0.3 Breaths per minute Standard Deviation 2.80	-0.6 Breaths per minute Standard Deviation 1.58	-0.3 Breaths per minute Standard Deviation 2.17
Change From Baseline in Respiratory Rate ON IV TREATMENT/DAY 4	-0.1 Breaths per minute Standard Deviation 1.78	-1.0 Breaths per minute Standard Deviation 1.94	-1.0 Breaths per minute Standard Deviation 1.41
Change From Baseline in Respiratory Rate ON IV TREATMENT/DAY 5	-0.4 Breaths per minute Standard Deviation 2.22	-0.7 Breaths per minute Standard Deviation 1.25	—
Change From Baseline in Respiratory Rate ON IV TREATMENT/DAY 6	-0.1 Breaths per minute Standard Deviation 2.33	-0.8 Breaths per minute Standard Deviation 1.47	—
Change From Baseline in Respiratory Rate ON IV TREATMENT/DAY 7	-1.2 Breaths per minute Standard Deviation 2.68	-1.0 Breaths per minute Standard Deviation 1.15	—
Change From Baseline in Respiratory Rate ON IV TREATMENT/DAY 10	-6.0 Breaths per minute Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Respiratory Rate ORAL - FIRST DAY	0.4 Breaths per minute Standard Deviation 2.33	0.3 Breaths per minute Standard Deviation 1.66	0.2 Breaths per minute Standard Deviation 1.92
Change From Baseline in Respiratory Rate ORAL - DAY 7-10	-0.2 Breaths per minute Standard Deviation 2.39	-0.1 Breaths per minute Standard Deviation 2.35	-0.2 Breaths per minute Standard Deviation 2.04
Change From Baseline in Respiratory Rate POST THERAPY DAY 12-18	0.0 Breaths per minute Standard Deviation 2.94	-0.3 Breaths per minute Standard Deviation 1.97	-0.4 Breaths per minute Standard Deviation 2.02
Change From Baseline in Respiratory Rate FOLLOW UP DAY 21-28	-0.6 Breaths per minute Standard Deviation 2.81	-0.3 Breaths per minute Standard Deviation 2.04	-0.5 Breaths per minute Standard Deviation 1.78
Change From Baseline in Respiratory Rate POST DOSE DAY 3-10	-2.0 Breaths per minute Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Respiratory Rate ON IV TREATMENT/DAY 8	-1.3 Breaths per minute Standard Deviation 4.16	—	—
Change From Baseline in Respiratory Rate ON IV TREATMENT/DAY 9	-4.0 Breaths per minute Standard Deviation 2.83	—	—

Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALT, ON IV TREATMENT/DAY 2	-1.9 International units per liter Standard Deviation 5.40	-1.0 International units per liter Standard Deviation 4.67	2.3 International units per liter Standard Deviation 14.57
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALT, ON IV TREATMENT/DAY 3	1.2 International units per liter Standard Deviation 14.63	1.4 International units per liter Standard Deviation 9.71	1.2 International units per liter Standard Deviation 6.30
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALT, ON IV TREATMENT/DAY 4	—	14.0 International units per liter Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALT, ON IV TREATMENT/DAY 5	9.3 International units per liter Standard Deviation 18.27	2.8 International units per liter Standard Deviation 9.89	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALT, ON IV TREATMENT/DAY 7	37.5 International units per liter Standard Deviation 19.09	18.5 International units per liter Standard Deviation 9.19	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALT, ORAL - FIRST DAY	3.6 International units per liter Standard Deviation 17.52	4.1 International units per liter Standard Deviation 11.58	5.7 International units per liter Standard Deviation 11.57
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALT, ORAL - DAY 7-10	6.6 International units per liter Standard Deviation 15.75	7.3 International units per liter Standard Deviation 17.74	6.3 International units per liter Standard Deviation 12.60
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALT, POST THERAPY DAY 12-18	12.8 International units per liter Standard Deviation 35.54	8.3 International units per liter Standard Deviation 21.90	4.2 International units per liter Standard Deviation 16.02
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALT, FOLLOW UP DAY 21-28	36.2 International units per liter Standard Deviation 53.78	27.8 International units per liter Standard Deviation 39.03	9.3 International units per liter Standard Deviation 4.62
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALT, POST DOSE DAY 3-10	22.0 International units per liter Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALP, ON IV TREATMENT/DAY 2	-1.4 International units per liter Standard Deviation 11.52	-1.3 International units per liter Standard Deviation 12.27	-4.0 International units per liter Standard Deviation 12.23
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALP, ON IV TREATMENT/DAY 3	1.8 International units per liter Standard Deviation 18.97	5.7 International units per liter Standard Deviation 14.17	-0.4 International units per liter Standard Deviation 6.17
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALP, ON IV TREATMENT/DAY 4	—	15.0 International units per liter Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALP, ON IV TREATMENT/DAY 5	-0.3 International units per liter Standard Deviation 13.01	5.0 International units per liter Standard Deviation 11.49	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALP, ON IV TREATMENT/DAY 7	3.0 International units per liter Standard Deviation 22.63	10.0 International units per liter Standard Deviation 21.21	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALP, ORAL - FIRST DAY	5.1 International units per liter Standard Deviation 19.30	4.0 International units per liter Standard Deviation 17.38	-0.4 International units per liter Standard Deviation 11.32
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALP, ORAL - DAY 7-10	3.8 International units per liter Standard Deviation 13.21	2.2 International units per liter Standard Deviation 19.16	-0.1 International units per liter Standard Deviation 11.17
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALP, POST THERAPY DAY 12-18	-0.8 International units per liter Standard Deviation 15.97	0.1 International units per liter Standard Deviation 16.16	-1.8 International units per liter Standard Deviation 11.72
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALP, FOLLOW UP DAY 21-28	4.6 International units per liter Standard Deviation 19.49	15.6 International units per liter Standard Deviation 20.84	-2.0 International units per liter Standard Deviation 3.61
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) ALP, POST DOSE DAY 3-10	17.0 International units per liter Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) AST, ON IV TREATMENT/DAY 2	-1.1 International units per liter Standard Deviation 6.58	0.7 International units per liter Standard Deviation 7.03	2.0 International units per liter Standard Deviation 10.85
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) AST, ON IV TREATMENT/DAY 3	1.6 International units per liter Standard Deviation 12.47	6.2 International units per liter Standard Deviation 22.30	6.9 International units per liter Standard Deviation 18.84
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) AST, ON IV TREATMENT/DAY 4	—	22.0 International units per liter Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) AST, ON IV TREATMENT/DAY 5	7.4 International units per liter Standard Deviation 17.95	4.2 International units per liter Standard Deviation 13.01	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) AST, ON IV TREATMENT/DAY 7	23.0 International units per liter Standard Deviation NA Only one participant was analyzed.	22.0 International units per liter Standard Deviation 0.00	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) AST, ORAL - FIRST DAY	4.3 International units per liter Standard Deviation 13.34	34 International units per liter Standard Deviation 13.52	6.3 International units per liter Standard Deviation 17.83
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) AST, ORAL - DAY 7-10	6.7 International units per liter Standard Deviation 12.08	6.8 International units per liter Standard Deviation 13.93	2.3 International units per liter Standard Deviation 17.44
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) AST, POST THERAPY DAY 12-18	10.9 International units per liter Standard Deviation 18.98	9.0 International units per liter Standard Deviation 15.53	0.8 International units per liter Standard Deviation 19.05
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) AST, FOLLOW UP DAY 21-28	16.2 International units per liter Standard Deviation 22.15	22.6 International units per liter Standard Deviation 29.90	5.3 International units per liter Standard Deviation 2.52
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) AST, POST DOSE DAY 3-10	9.0 International units per liter Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) GGT, ON IV TREATMENT/DAY 2	-1.5 International units per liter Standard Deviation 7.68	-1.9 International units per liter Standard Deviation 8.10	-1.4 International units per liter Standard Deviation 10.15
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) GGT, ON IV TREATMENT/DAY 3	1.7 International units per liter Standard Deviation 18.66	3.8 International units per liter Standard Deviation 12.23	1.9 International units per liter Standard Deviation 5.16
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) GGT, ON IV TREATMENT/DAY 4	—	-4.0 International units per liter Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) GGT, ON IV TREATMENT/DAY 5	3.3 International units per liter Standard Deviation 21.70	-2.5 International units per liter Standard Deviation 5.21	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) GGT, ON IV TREATMENT/DAY 7	25.5 International units per liter Standard Deviation 0.71	-3.0 International units per liter Standard Deviation 12.73	—
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) GGT, ORAL - FIRST DAY	3.3 International units per liter Standard Deviation 20.16	4.5 International units per liter Standard Deviation 16.25	-1.1 International units per liter Standard Deviation 10.95
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) GGT, ORAL - DAY 7-10	3.6 International units per liter Standard Deviation 17.06	7.5 International units per liter Standard Deviation 19.89	-2.2 International units per liter Standard Deviation 14.75
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) GGT, POST THERAPY DAY 12-18	3.0 International units per liter Standard Deviation 15.60	5.3 International units per liter Standard Deviation 21.08	-3.9 International units per liter Standard Deviation 16.80
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) GGT, FOLLOW UP DAY 21-28	6.0 International units per liter Standard Deviation 13.56	64.0 International units per liter Standard Deviation 89.91	3.0 International units per liter Standard Deviation NA Only one participant was analyzed.
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Follicle Stimulating Hormone (FSH) and Gamma Glutamyl Transferase (GGT) GGT, POST DOSE DAY 3-10	39.0 International units per liter Standard Deviation NA Only one participant was analyzed.	—	—

Measure	Gepotidacin 750 mg q12h n=58 Participants Participants received GSK2140944 750 mg IV every 12 hours (q12h; BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 1500 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 750 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q12h n=39 Participants Participants received GSK2140944 1000 mg IV q12h (BID) on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h (BID) at investigator's discretion or continued to receive GSK2140944 1000 mg IV q12h (BID) from Day 3 to Day 10.	Gepotidacin 1000 mg q8h n=25 Participants Participants received GSK21409447 1000 mg IV q8h TID on Day 1 and Day 2. Participants switched to oral GSK2140944 2000 mg q12h TID at investigator's discretion or continued to receive GSK2140944 1000 mg IV q8h TID from Day 3 to Day 10.
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Bilirubin, ON IV TREATMENT/DAY 2	-1.9 Micromoles per liter Standard Deviation 3.22	-1.3 Micromoles per liter Standard Deviation 2.87	-2.4 Micromoles per liter Standard Deviation 3.34
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Bilirubin, ON IV TREATMENT/DAY 3	-2.8 Micromoles per liter Standard Deviation 4.42	-1.0 Micromoles per liter Standard Deviation 3.61	-2.2 Micromoles per liter Standard Deviation 2.73
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Bilirubin, ON IV TREATMENT/DAY 4	—	-4.0 Micromoles per liter Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Bilirubin, ON IV TREATMENT/DAY 5	-2.8 Micromoles per liter Standard Deviation 4.64	-4.0 Micromoles per liter Standard Deviation 2.53	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Bilirubin, ON IV TREATMENT/DAY 7	0.0 Micromoles per liter Standard Deviation 0.0	-4.0 Micromoles per liter Standard Deviation 0.00	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Bilirubin, ORAL - FIRST DAY	-1.9 Micromoles per liter Standard Deviation 3.87	-1.7 Micromoles per liter Standard Deviation 3.12	-2.4 Micromoles per liter Standard Deviation 2.69
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Bilirubin, ORAL - DAY 7-10	-0.9 Micromoles per liter Standard Deviation 4.17	-0.7 Micromoles per liter Standard Deviation 2.49	-1.7 Micromoles per liter Standard Deviation 2.55
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Urate, ORAL - DAY 7-10	51.6 Micromoles per liter Standard Deviation 55.31	67.0 Micromoles per liter Standard Deviation 69.79	55.2 Micromoles per liter Standard Deviation 65.32
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Bilirubin, POST THERAPY DAY 12-18	-1.0 Micromoles per liter Standard Deviation 4.35	-0.5 Micromoles per liter Standard Deviation 3.25	-1.4 Micromoles per liter Standard Deviation 3.83
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Bilirubin, FOLLOW UP DAY 21-28	0.0 Micromoles per liter Standard Deviation 8.72	0.0 Micromoles per liter Standard Deviation 4.69	-1.3 Micromoles per liter Standard Deviation 6.11
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Bilirubin, POST DOSE DAY 3-10	-2.0 Micromoles per liter Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Creatinine, ON IV TREATMENT/DAY 2	3.45 Micromoles per liter Standard Deviation 11.885	-2.33 Micromoles per liter Standard Deviation 19.886	0.66 Micromoles per liter Standard Deviation 8.711
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Creatinine, ON IV TREATMENT/DAY 3	1.30 Micromoles per liter Standard Deviation 10.462	-5.35 Micromoles per liter Standard Deviation 28.787	-3.93 Micromoles per liter Standard Deviation 12.123
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Creatinine, ON IV TREATMENT/DAY 4	—	-1.70 Micromoles per liter Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Creatinine, ON IV TREATMENT/DAY 5	-0.91 Micromoles per liter Standard Deviation 10.541	7.37 Micromoles per liter Standard Deviation 8.704	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Creatinine, ON IV TREATMENT/DAY 7	8.40 Micromoles per liter Standard Deviation 10.607	6.65 Micromoles per liter Standard Deviation 8.132	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Creatinine, ORAL - FIRST DAY	4.22 Micromoles per liter Standard Deviation 11.115	-3.78 Micromoles per liter Standard Deviation 27.598	2.37 Micromoles per liter Standard Deviation 10.268
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Creatinine, ORAL - DAY 7-10	4.65 Micromoles per liter Standard Deviation 9.930	0.72 Micromoles per liter Standard Deviation 30.659	4.13 Micromoles per liter Standard Deviation 9.518
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Creatinine, POST THERAPY DAY 12-18	3.82 Micromoles per liter Standard Deviation 10.641	2.93 Micromoles per liter Standard Deviation 26.419	2.08 Micromoles per liter Standard Deviation 9.293
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Creatinine, FOLLOW UP DAY 21-28	9.92 Micromoles per liter Standard Deviation 12.289	-1.80 Micromoles per liter Standard Deviation 2.846	2.70 Micromoles per liter Standard Deviation NA Only one participant was analyzed.
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Creatinine, POST DOSE DAY 3-10	-2.70 Micromoles per liter Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Direct Bilirubin, ON IV TREATMENT/DAY 2	-0.3 Micromoles per liter Standard Deviation 2.09	-0.6 Micromoles per liter Standard Deviation 1.79	-1.1 Micromoles per liter Standard Deviation 2.28
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Direct Bilirubin, ON IV TREATMENT/DAY 3	-0.2 Micromoles per liter Standard Deviation 2.33	-0.7 Micromoles per liter Standard Deviation 1.83	-1.3 Micromoles per liter Standard Deviation 2.24
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Direct Bilirubin, ON IV TREATMENT/DAY 4	—	-2.0 Micromoles per liter Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Direct Bilirubin, ON IV TREATMENT/DAY 5	-1.0 Micromoles per liter Standard Deviation 1.94	-0.7 Micromoles per liter Standard Deviation 2.73	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Direct Bilirubin, ON IV TREATMENT/DAY 7	-1.0 Micromoles per liter Standard Deviation 1.41	-3.0 Micromoles per liter Standard Deviation 1.41	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Direct Bilirubin, ORAL - FIRST DAY	-0.4 Micromoles per liter Standard Deviation 2.15	-0.2 Micromoles per liter Standard Deviation 2.19	-1.0 Micromoles per liter Standard Deviation 2.08
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Direct Bilirubin, ORAL - DAY 7-10	0.0 Micromoles per liter Standard Deviation 1.95	0.0 Micromoles per liter Standard Deviation 2.10	-1.0 Micromoles per liter Standard Deviation 2.16
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Direct Bilirubin, POST THERAPY DAY 12-18	-0.3 Micromoles per liter Standard Deviation 2.02	0.0 Micromoles per liter Standard Deviation 1.68	-1.2 Micromoles per liter Standard Deviation 2.03
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Direct Bilirubin, FOLLOW UP DAY 21-28	1.5 Micromoles per liter Standard Deviation 5.00	0.5 Micromoles per liter Standard Deviation 1.91	0.0 Micromoles per liter Standard Deviation NA Only one participant was analyzed.
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Direct Bilirubin, POST DOSE DAY 3-10	0.0 Micromoles per liter Standard Deviation NA Only one participant was analyzed.	—	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Urate, ON IV TREATMENT/DAY 2	1.2 Micromoles per liter Standard Deviation 44.16	-11.7 Micromoles per liter Standard Deviation 42.46	-17.1 Micromoles per liter Standard Deviation 50.43
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Urate, ON IV TREATMENT/DAY 3	4.2 Micromoles per liter Standard Deviation 66.33	5.7 Micromoles per liter Standard Deviation 52.02	-14.4 Micromoles per liter Standard Deviation 97.10
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Urate, POST THERAPY DAY 12-18	60.8 Micromoles per liter Standard Deviation 73.88	49.4 Micromoles per liter Standard Deviation 83.24	45.3 Micromoles per liter Standard Deviation 60.31
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Urate, ON IV TREATMENT/DAY 4	—	60.0 Micromoles per liter Standard Deviation NA Only one participant was analyzed.	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Urate, ON IV TREATMENT/DAY 5	26.0 Micromoles per liter Standard Deviation 89.47	46.7 Micromoles per liter Standard Deviation 50.86	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Urate, ON IV TREATMENT/DAY 7	10.0 Micromoles per liter Standard Deviation 169.71	90.0 Micromoles per liter Standard Deviation 28.28	—
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Urate, ORAL - FIRST DAY	16.3 Micromoles per liter Standard Deviation 52.46	2.9 Micromoles per liter Standard Deviation 67.26	-1.3 Micromoles per liter Standard Deviation 67.71
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Urate, FOLLOW UP DAY 21-28	7.5 Micromoles per liter Standard Deviation 80.16	10.0 Micromoles per liter Standard Deviation 102.31	140.0 Micromoles per liter Standard Deviation NA Only one participant was analyzed.
Change From Baseline in Clinical Chemistry Parameters: Bilirubin, Creatinine, Direct Bilirubin and Urate Urate, POST DOSE DAY 3-10	70.0 Micromoles per liter Standard Deviation NA Only one participant was analyzed.	—	—